85,000 CAPiTA participants

EQ-5D questionnaire for baseline measurement (October 2008 – January 2010)

**With** baseline EQ-5D score and consent
~25,500 persons
= CHO-CAP baseline cohort

Develop CAP (i.e. diseased persons)
‘CAP cases’
~600 persons
If consent, included in **diseased cohort**.
Contact at 0, 1, 6 and 12 months

Unaffected persons (i.e. no CAP)
‘controls’
~24,900 persons
If consent, 2 controls per CAP included in **non-diseased cohort**, by matching on:
• Age
• Sex
• Baseline EQ-5D score
Contact at 0, 1, 6 and 12 months.

**Without** baseline EQ-5D score
~59,500 persons

Develop CAP (i.e. diseased persons)
~1,400 persons

Unaffected persons (i.e. no CAP)
~58,100 persons

Information on mortality, withdrawal, loss to follow-up and some information on socio-demographic data and comorbidity from main trial for all participants;
Information on hospital resources used from the Etio-CAP substudy and main trial CAP cases.